Published in Gene Therapy Weekly, March 3rd, 2005
As part of the transduction-signaling technology, these novel compounds could lead to new highly effective treatments for some forms of cancer.
Financial details were not disclosed.
Dr. Laszlo Urge, CEO of ComGenex, Inc., commented, "As Echelon is aggressively pursuing these drug-discovery and -development programs in the field of oncology, we think we made the best choice....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.